BACKGROUND/AIMS: In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines. METHODS: The fasting serum acylcarnitine concentrations were determined in 49 T1D, 38 T2D and 38 MetS patients and 40 controls by isotope dilution electrospray ionization tandem mass spectrometry. RESULTS: The acylcarnitine profiles of the 3patient groups shared elements with the controls. Considerably higher levels of almost all short-chain acylcarnitines (p < 0.05) and lower levels of some long-chain acylcarnitines were detected in T2D and MetS patients. The amounts of C3 and C4 carnitine were higher and most of the medium-chain and long-chain acylcarnitine levels were lower (p < 0.05) in T1D and MetS patients than in the controls. In T1D and T2D, the levels of C3 and C4 acylcarnitines were markedly elevated and some long-chain acylcarnitines were lower than the controls (p < 0.05). Moreover, significantly lower concentrations of free- and total carnitine were observed in T1D patients (p < 0.05). CONCLUSIONS: Profound alterations were detected in acylcarnitine profiles in the 3 patient groups. Similarities in the patterns suggest different degrees of involvement of the same metabolic systems in a systems biology approach.
BACKGROUND/AIMS: In type 1 diabetes (T1D), type 2 diabetes (T2D) and metabolic syndrome (MetS), the associated complex metabolomic changes in the involvement of carnitine metabolism in total carnitine ester level has already been documented; here we extended the investigations to the individual acylcarnitines. METHODS: The fasting serum acylcarnitine concentrations were determined in 49 T1D, 38 T2D and 38 MetS patients and 40 controls by isotope dilution electrospray ionization tandem mass spectrometry. RESULTS: The acylcarnitine profiles of the 3patient groups shared elements with the controls. Considerably higher levels of almost all short-chain acylcarnitines (p < 0.05) and lower levels of some long-chainacylcarnitines were detected in T2D and MetS patients. The amounts of C3 and C4 carnitine were higher and most of the medium-chain and long-chainacylcarnitine levels were lower (p < 0.05) in T1D and MetS patients than in the controls. In T1D and T2D, the levels of C3 and C4 acylcarnitines were markedly elevated and some long-chainacylcarnitines were lower than the controls (p < 0.05). Moreover, significantly lower concentrations of free- and total carnitine were observed in T1D patients (p < 0.05). CONCLUSIONS: Profound alterations were detected in acylcarnitine profiles in the 3 patient groups. Similarities in the patterns suggest different degrees of involvement of the same metabolic systems in a systems biology approach.
Authors: Kelli K Ryckman; Caitlin J Smith; Laura L Jelliffe-Pawlowski; Allison M Momany; Stanton L Berberich; Jeffrey C Murray Journal: Hum Genet Date: 2014-05-22 Impact factor: 4.132
Authors: Samantha Molsberry; Kjetil Bjornevik; Katherine C Hughes; Zhongli Joel Zhang; Sarah Jeanfavre; Clary Clish; Brian Healy; Michael Schwarzschild; Alberto Ascherio Journal: J Parkinsons Dis Date: 2020 Impact factor: 5.568
Authors: Hye In Kim; Johannes Raffler; Wenyun Lu; Jung-Jin Lee; Deepti Abbey; Danish Saleheen; Joshua D Rabinowitz; Michael J Bennett; Nicholas J Hand; Christopher Brown; Daniel J Rader Journal: Am J Hum Genet Date: 2017-09-21 Impact factor: 11.025
Authors: Battsetseg Batchuluun; Dana Al Rijjal; Kacey J Prentice; Judith A Eversley; Elena Burdett; Haneesha Mohan; Alpana Bhattacharjee; Erica P Gunderson; Ying Liu; Michael B Wheeler Journal: Diabetes Date: 2018-02-07 Impact factor: 9.461